Cited 2 times in
The Efficacy of Mycophenolate Mofetil in Remission Maintenance Therapy for Microscopic Polyangiitis and Granulomatosis with Polyangiitis
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 박용범 | - |
dc.contributor.author | 송정식 | - |
dc.contributor.author | 안성수 | - |
dc.contributor.author | 이상원 | - |
dc.contributor.author | 이은주 | - |
dc.contributor.author | 표정윤 | - |
dc.date.accessioned | 2021-09-29T00:38:20Z | - |
dc.date.available | 2021-09-29T00:38:20Z | - |
dc.date.issued | 2021-06 | - |
dc.identifier.issn | 0513-5796 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/183967 | - |
dc.description.abstract | Purpose: The present study compared the efficacy of mycophenolate mofetil (MMF) with that of azathioprine (AZA) in Korean patients with microscopic polyangiitis (MPA) and granulomatosis with polyangiitis (GPA). Materials and methods: The medical records of 69 patients with MPA and GPA who received cyclophosphamide and subsequently received AZA or MMF for remission maintenance therapy were reviewed. All-cause mortality, relapse, end-stage renal disease (ESRD), cerebrovascular accident, and cardiovascular disease were evaluated as poor outcomes. Having a lower Birmingham Vasculitis Activity Score (BVAS) was defined as the lowest tertile of BVAS (BVAS ≤11 in this study). Results: In comparative analysis of the occurrence of poor outcomes among patients taking AZA only, MMF only, and MMF after AZA, patients taking MMF only exhibited a significantly lower cumulative ESRD-free survival rate than patients taking AZA only (p=0.028). In terms of ESRD occurrence between the groups based on BVAS at diagnosis, among patients with MPA and GPA with higher BVAS at diagnosis, patients taking MMF only exhibited a significantly lower cumulative ESRD-free survival rate than those taking AZA only (p=0.047). Among patients with MPA and GPA with the lowest tertile of BVAS at diagnosis, cumulative ESRD-free survival rates did not differ. Conclusion: With regard to ESRD occurrence, the efficacy of MMF in remission maintenance therapy was less effective than AZA in patients with MPA and GPA. However, among patients with lower BVAS, there was no difference in the occurrence of poor outcomes between patients taking MMF and those taking AZA. | - |
dc.description.statementOfResponsibility | open | - |
dc.language | English | - |
dc.publisher | Yonsei University | - |
dc.relation.isPartOf | YONSEI MEDICAL JOURNAL | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.subject.MESH | Azathioprine / therapeutic use | - |
dc.subject.MESH | Granulomatosis with Polyangiitis* / drug therapy | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Immunosuppressive Agents / therapeutic use | - |
dc.subject.MESH | Microscopic Polyangiitis* / drug therapy | - |
dc.subject.MESH | Mycophenolic Acid / therapeutic use | - |
dc.subject.MESH | Treatment Outcome | - |
dc.title | The Efficacy of Mycophenolate Mofetil in Remission Maintenance Therapy for Microscopic Polyangiitis and Granulomatosis with Polyangiitis | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학교실) | - |
dc.contributor.googleauthor | Jung Yoon Pyo | - |
dc.contributor.googleauthor | Lucy Eunju Lee | - |
dc.contributor.googleauthor | Sung Soo Ahn | - |
dc.contributor.googleauthor | Jason Jungsik Song | - |
dc.contributor.googleauthor | Yong Beom Park | - |
dc.contributor.googleauthor | Sang Won Lee | - |
dc.identifier.doi | 10.3349/ymj.2021.62.6.494 | - |
dc.contributor.localId | A01579 | - |
dc.contributor.localId | A02057 | - |
dc.contributor.localId | A02233 | - |
dc.contributor.localId | A02824 | - |
dc.contributor.localId | A05935 | - |
dc.contributor.localId | A04244 | - |
dc.relation.journalcode | J02813 | - |
dc.identifier.eissn | 1976-2437 | - |
dc.identifier.pmid | 34027636 | - |
dc.subject.keyword | Mycophenolate mofetil | - |
dc.subject.keyword | antineutrophil cytoplasmic antibody-associated vasculitis | - |
dc.subject.keyword | azathioprine | - |
dc.subject.keyword | end-stage renal disease | - |
dc.subject.keyword | poor outcomes | - |
dc.contributor.alternativeName | Park, Yong Beom | - |
dc.contributor.affiliatedAuthor | 박용범 | - |
dc.contributor.affiliatedAuthor | 송정식 | - |
dc.contributor.affiliatedAuthor | 안성수 | - |
dc.contributor.affiliatedAuthor | 이상원 | - |
dc.contributor.affiliatedAuthor | 이은주 | - |
dc.contributor.affiliatedAuthor | 표정윤 | - |
dc.citation.volume | 62 | - |
dc.citation.number | 6 | - |
dc.citation.startPage | 494 | - |
dc.citation.endPage | 502 | - |
dc.identifier.bibliographicCitation | YONSEI MEDICAL JOURNAL, Vol.62(6) : 494-502, 2021-06 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.